Pitavastatin + ezetimibe
Pitavastatin + ezetimibe has been studied in 2 papers since 2026: none in people yet, 2 reviews; 2 in the past year. No study of it in people or animals has been published yet. The newest paper, Nov 2, 2026: “Efficacy and Safety of Pitavastatin Plus Ezetimibe versus Pitavastatin Monotherapy in Adults with Hypercholesterolemia”.
3 new papers in 30 daysSee all 6 papers on pitavastatin + ezetimibe
At a glance
The findings reach people, from one lab or study. 2 independent labs in 2 countries; 2 trials, 2 about aging.
None of its findings points the other way.
- 2 independent labs in 2 countries
- 2 trials, 2 about aging
- 2 of 2 trials sponsored by its developers
What did studies of pitavastatin + ezetimibe find?
3Studies of pitavastatin + ezetimibe measured 3 outcomes: overall adverse events, LDL cholesterol and LDL.
Overall adverse events
no changein humans1RR 1.05
1 study
Overall adverse events
no changein humans1RR 1.05
Pitavastatin + ezetimibe showed no clear effect on overall adverse events in humans (hypercholesterolemia or dyslipidemia; compared with pitavastatin monotherapy) (RR 1.05; 95% CI 0.89–1.25).
“The incidence of overall adverse events was similar between treatment groups (RR 1.05; 95% CI 0.89-1.25; I 2 = 0%).”
Reviewhypercholesterolemia or dyslipidemia; compared with pitavastatin monotherapyn = 2,403
AHA Scientific Sessions 2026 abstract
LDL cholesterol
downin humans1
1 study
LDL cholesterol
downin humans1
Pitavastatin + ezetimibe decreases LDL cholesterol in humans (hypercholesterolemia or dyslipidemia; compared with pitavastatin monotherapy) (MD −22.54 mg/dL; 95% CI −25.47 to −19.61).
“Compared with pitavastatin monotherapy, pitavastatin plus ezetimibe significantly reduced LDL-C levels”
Reviewhypercholesterolemia or dyslipidemia; compared with pitavastatin monotherapyn = 2,403
AHA Scientific Sessions 2026 abstract
LDL
downin humans1
1 study
LDL
downin humans1
Pitavastatin + ezetimibe decreases LDL in humans (network meta-analysis of LDL reduction).
“For LDL reduction, the combination of moderate-intensity pitavastatin and ezetimibe was the most effective”
Reviewnetwork meta-analysis of LDL reductionmoderate-intensityn = 43,625
Journal of geriatric cardiology : JGC
Has pitavastatin + ezetimibe been tested in people?
2 of 2 about agingNo study of it in people has been published yet.
About aging
Phase 4Active, not recruiting
Phase 4Not yet recruiting